David L Suskind1, Ghassan Wahbeh2, Stanley A Cohen3, Christopher J Damman4, Jani Klein2, Kim Braly2, Michele Shaffer2,5, Dale Lee2. 1. Department of Pediatrics, Seattle Children's Hospital, University of Washington, 4800 Sandpoint Way NE, Seattle, WA, 98105, USA. David.Suskind@seattlechildrens.org. 2. Department of Pediatrics, Seattle Children's Hospital, University of Washington, 4800 Sandpoint Way NE, Seattle, WA, 98105, USA. 3. Children's Center for Digestive Health Care, Children's Healthcare of Atlanta, Atlanta, GA, USA. 4. Department of Medicine, Division of Gastroenterology, University of Washington Medical Center, Seattle, WA, USA. 5. Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, WA, USA.
Abstract
BACKGROUND: Recent studies suggest that dietary therapy may be effective for patients with inflammatory bowel disease (IBD), but limited published data exist on the usage and efficacy of dietary therapy. AIM: To evaluate the perspective of IBD patients using the specific carbohydrate diet (SCD). METHODS: An anonymous online survey was conducted using REDCap, a Web-based survey tool. Survey links were sent to known Web sites as well as support groups in an attempt to characterize patient utilization of the SCD and perception of efficacy of the SCD. RESULTS: There were 417 respondents of the online survey on the SCD with IBD. Mean age for individuals on the SCD was 34.9 ± 16.4 years. Seventy percent were female. Forty-seven percent had Crohn's disease, 43 % had ulcerative colitis, and 10 % had indeterminate colitis. Individuals perceived clinical improvement on the SCD. Four percent reported clinical remission prior to the SCD, while 33 % reported remission at 2 months after initiation of the SCD, and 42 % at both 6 and 12 months. For those reporting clinical remission, 13 % reported time to achieve remission of less than 2 weeks, 17 % reported 2 weeks to a month, 36 % reported 1-3 months, and 34 % reported greater than 3 months. For individuals who reported reaching remission, 47 % of individuals reported associated improvement in abnormal laboratory values. CONCLUSIONS: The SCD is utilized by many patients as a primary and adjunct therapy for IBD. Most patients perceive clinical benefit to use of the SCD.
BACKGROUND: Recent studies suggest that dietary therapy may be effective for patients with inflammatory bowel disease (IBD), but limited published data exist on the usage and efficacy of dietary therapy. AIM: To evaluate the perspective of IBD patients using the specific carbohydrate diet (SCD). METHODS: An anonymous online survey was conducted using REDCap, a Web-based survey tool. Survey links were sent to known Web sites as well as support groups in an attempt to characterize patient utilization of the SCD and perception of efficacy of the SCD. RESULTS: There were 417 respondents of the online survey on the SCD with IBD. Mean age for individuals on the SCD was 34.9 ± 16.4 years. Seventy percent were female. Forty-seven percent had Crohn's disease, 43 % had ulcerative colitis, and 10 % had indeterminate colitis. Individuals perceived clinical improvement on the SCD. Four percent reported clinical remission prior to the SCD, while 33 % reported remission at 2 months after initiation of the SCD, and 42 % at both 6 and 12 months. For those reporting clinical remission, 13 % reported time to achieve remission of less than 2 weeks, 17 % reported 2 weeks to a month, 36 % reported 1-3 months, and 34 % reported greater than 3 months. For individuals who reported reaching remission, 47 % of individuals reported associated improvement in abnormal laboratory values. CONCLUSIONS: The SCD is utilized by many patients as a primary and adjunct therapy for IBD. Most patients perceive clinical benefit to use of the SCD.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Rachel L Randell; Millie D Long; Suzanne F Cook; Christina E D Wrennall; Wenli Chen; Christopher F Martin; Kristen Anton; Robert S Sandler; Michael D Kappelman Journal: Inflamm Bowel Dis Date: 2014-03 Impact factor: 5.325
Authors: Margarita Martinez-Medina; Jérémy Denizot; Nicolas Dreux; Frédéric Robin; Elisabeth Billard; Richard Bonnet; Arlette Darfeuille-Michaud; Nicolas Barnich Journal: Gut Date: 2013-04-18 Impact factor: 23.059
Authors: Stanley A Cohen; Benjamin D Gold; Salvatore Oliva; Jeffery Lewis; Angela Stallworth; Bailey Koch; Laura Eshee; David Mason Journal: J Pediatr Gastroenterol Nutr Date: 2014-10 Impact factor: 2.839
Authors: Benoit Chassaing; Omry Koren; Julia K Goodrich; Angela C Poole; Shanthi Srinivasan; Ruth E Ley; Andrew T Gewirtz Journal: Nature Date: 2015-02-25 Impact factor: 49.962
Authors: Kimberly Braly; Nila Williamson; Michele L Shaffer; Dale Lee; Ghassan Wahbeh; Jani Klein; Matthew Giefer; David L Suskind Journal: J Pediatr Gastroenterol Nutr Date: 2017-11 Impact factor: 2.839
Authors: Nicolaus Nazarenkov; Kristina Seeger; Lori Beeken; Ashwin N Ananthakrishnan; Hamed Khalili; James D Lewis; Gauree Gupta Konijeti Journal: Gastroenterol Hepatol (N Y) Date: 2019-03